On June 4, Hong Kong-listed innovative pharmaceutical stocks remained active, with XuanZhu Bio-B (02575.HK) advancing throughout the trading session. By market close, the company's shares rose 7.12% to HK$17.61, with turnover reaching approximately HK$64.74 million and trading volume of 3.71 million shares. The stock climbed as much as 12.53% intraday to a record high of HK$18.50, marking its highest level since listing. Supported by continued commercialization of key products and progress in its international expansion strategy, the company has become one of the market's focal points.

(Image Source: uSMART HK app)

Three Core Products Enter Commercialization Harvest Phase

As an innovation-driven biopharmaceutical company, XuanZhu Bio has continued to increase R&D investment in recent years, gradually building a diversified pipeline covering gastrointestinal diseases, oncology, and other therapeutic areas. With multiple key products receiving regulatory approvals, the company is transitioning from a research-focused stage to a commercialization-driven growth phase.

Currently, the company's self-developed Annalazole has been approved for the treatment of duodenal ulcers. As a next-generation acid-suppressing therapy, development efforts for additional indications, including Helicobacter pylori infection and reflux esophagitis, are ongoing, potentially broadening its market reach in the future.

Meanwhile, the company's flagship oncology product Pyrotinib has been approved for monotherapy in previously treated patients with HR+/HER2− advanced breast cancer. It is currently the only CDK4/6 inhibitor in China approved for this specific indication. Industry observers believe that, supported by its differentiated positioning and demonstrated clinical value, the product is well positioned to capture market share in the breast cancer treatment market.

Another key product, Dironalcib, targets ALK-positive non-small cell lung cancer (NSCLC). Clinical data have shown encouraging efficacy and disease-control performance among patients with brain metastases, highlighting its competitive potential within the ALK inhibitor market.

Licensing Agreement Marks Key Milestone in Global Expansion

In addition to accelerating domestic commercialization, XuanZhu Bio has also achieved significant progress in its international strategy. In April, the company announced a licensing and supply agreement with Boston Oncology CGT, granting the partner development, registration, and commercialization rights for Pyrotinib and Dironalcib across multiple countries and regions in the Middle East and North Africa (MENA).

Under the agreement, XuanZhu Bio is entitled to receive an upfront payment, potential milestone payments exceeding US$100 million in aggregate, and future sales-based royalties.

Market analysts believe the partnership not only enhances the international visibility of the company's innovative drug portfolio but also demonstrates growing recognition of its R&D capabilities in overseas markets. As more Chinese biotech companies pursue globalization strategies, overseas licensing has increasingly become an important growth driver for innovative drug commercialization. Leveraging its partner's local market expertise, distribution channels, and commercialization capabilities, XuanZhu Bio is expected to accelerate market entry in the region and generate new sources of revenue growth.

Commercialization Momentum Strengthens Long-Term Growth Narrative

In recent years, the innovative pharmaceutical industry has gradually shifted its focus from pure R&D investment toward commercialization execution. As a result, valuation frameworks are increasingly emphasizing product sales performance and profitability rather than pipeline expectations alone.

With Annalazole, Pyrotinib, and Dironalcib entering the commercialization stage and expanding market penetration, the company's revenue base is expected to continue growing. At the same time, ongoing indication expansion programs and overseas market development efforts are likely to further enhance the lifecycle value of its products.

From a market perspective, investor interest in innovative pharmaceutical companies with proven commercialization capabilities has strengthened noticeably. XuanZhu Bio's intraday gain of more than 12% and record-high share price on June 4 reflected the market's positive expectations for its future growth prospects.

Supported by the commercialization ramp-up of key products, continued progress in overseas licensing partnerships, and improving industry sentiment toward innovative drugs, XuanZhu Bio is gradually establishing a development model centered on innovation-driven R&D, commercialization execution, and global expansion, with significant long-term growth potential warranting continued attention from investors.

How to Buy XuanZhu Bio on uSMART

After logging into the uSMART HK app, click the “Search” button in the top-right corner of the page, enter the ticker code (02575.HK) , and navigate to the details page to view transaction details and historical trends. Click the “Trade” button in the bottom-right corner, select the trade type, and submit your order after filling in the transaction conditions.

(Image Source: uSMART HK app)